SEHK:2171Biotechs
Assessing CARsgen Therapeutics Holdings’ Valuation After New CAR T-Cell Manufacturing Cooperation News
CARsgen Therapeutics Holdings (SEHK:2171) has signed cooperation agreements via its subsidiary CARsgen Diagnostics with Shanghai Jingong Enterprise to build a commercial CAR T-cell manufacturing base in Shanghai, a move closely linked to its commercialization plans.
See our latest analysis for CARsgen Therapeutics Holdings.
The cooperation news comes as momentum in CARsgen Therapeutics Holdings' share price has recently picked up, with a 1-day share price return of 4.65% and a 7-day share...